TITLE

Glaxo introduces villain in Relenza ads: Newman

AUTHOR(S)
Petrecca, Laura; Goetzl, David
PUB. DATE
November 1999
SOURCE
Advertising Age;11/8/1999, Vol. 70 Issue 46, p16
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on the involvement of TV actor Wayne Knight in an advertising campaign for the Relenza inhalant from pharmaceutical company Glaxo Wellcome in the U.S. as of November 1999. In the Relenza campaign, Knight's character travels to households via bus to spread his germs. Supporting print advertisements feature a mug shot of Knight imposed on a poster. The campaign, valued at $30 million, is the first work developed by advertising agency Saatchi & Saatchi for Glaxo Wellcome. Relenza and Tamiflu, developed by Hoffman-La Roche, are drugs designed to alleviate flu symptoms, and both are expected to spend millions on competing direct-to-consumer campaigns through the winter.
ACCESSION #
2459052

 

Related Articles

  • image of the Week.  // Advertising Age;6/21/1999, Vol. 70 Issue 26, p52 

    This section shows an image from a print advertising campaign for Glaxo Wellcome's Zyban anti-smoking treatment.

  • Relenza to launch with ad support.  // Drug Store News;8/30/99, Vol. 21 Issue 13, pCP12 

    Reports on the plan of Glaxo Wellcome to launch a full multimedia advertising campaign for Relenza drug. Administration of the drug; Details on the advertising campaign.

  • Managing a messaging system.  // Life Science Today;Jun2000, Vol. 1 Issue 3, p24 

    Focuses on the implementation of management program for messaging system at Glaxo Wellcome PLC in Great Britain. Establishment of Service Level agreements by the Messaging Team; Causes of messaging system failure; Importance of systems management solutions for messaging services at Glaxo.

  • A GIANT BATTLES ITS DRUG DEPENDENCY. EVANS, RICHARD // Fortune;8/5/1996, Vol. 134 Issue 3, p88 

    Reports on ways in which pharmaceutical giant Glaxo Wellcome is trying to end its financial dependence on two medicines whose patents run out in 1997. The company receiving 40 percent of its revenues from Zantac ulcer remedy and herpes treatment Zovirax; Development of newer products to treat...

  • COMPANY CV.  // Marketing (00253650);1/20/2000, p70 

    Focuses on pharmaceutical firm, Glaxo Wellcome. Company facts; Turnover; Profit; Employees; Annual advertising spendings; Advertising agencies; Media buyer; Top marketers; Headquarters in Great Britain; Web site.

  • Glaxo Wellcome opens facility in Brazil.  // Chemical Business;Nov98, Vol. 12 Issue 11, p75 

    Reports on Glaxo Wellcome's opening of a pharmaceutical production facility in Brazil. Facility's start of production of tablets in December 1998.

  • Glaxo recruits patients against formularies. Dickinson, James G. // Medical Marketing & Media;Feb99, Vol. 34 Issue 2, p36 

    Reports on Glaxo Wellcome PLC's launching of a direct-to-mail promotion aimed at enlisting patient support against managed care formularies that discriminate against its bronchodilator Severent.

  • ChiRex buys Glaxo plant.  // Chemical Market Reporter;11/03/97, Vol. 252 Issue 18, p7 

    Reports on ChiRex Inc.'s acquisition of Glaxo Wellcome PLC's cGMP pharmaceutical production facility in Annan, Scotland.

  • Marketing gets some credit for Glaxo success. SKB merger wins stockholder OK.  // Medical Marketing & Media;Sep2000, Vol. 35 Issue 9, p18 

    Focuses on an increase in the sales of United States-based pharmaceutical firm Glaxo Wellcome in the first half of year 2000. Result of increased investment in marketing; Expansion of sales force; Direct-to-consumer advertising campaign for Lotronex.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics